Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$27,000.00

Enhancing Chimeric Antigen Receptor (CAR) T Cell Therapy in Alveolar Soft Part Sarcoma through Extrinsic and Intrinsic Inhibition of the PD1/PDL1 Immune Checkpoint Axis

EF 2024-25

Résumé
Background Alveolar soft part sarcoma (ASPS) is a highly metastatic cancer that is poorly managed by traditional treatment approaches. A new strategy known as chimeric antigen receptor (CAR) T cell therapy, where specialized killing cells of a patient immune system called T cells are engineered to selectively target their cancer, has proven effective. In a first-in-human trial, a CAR T therapy developed by our lab successfully eliminated many metastatic growths in a patient with ASPS; however, larger growths were non-responsive, likely due to activation of immune checkpoints by the cancer that suppress T cell activity. Further analysis of a non-responsive growth identified PDL1 as a highly expressed checkpoint protein, which sends inhibitory signals through interactions with its receptor, PD1, on T cells. Interestingly, atezolizumab, a PDL1 inhibitor, was recently approved for treating ASPS and may augment CAR T therapy. Enhancing CAR T Therapy with atezolizumab: In an ASPS mouse model, my initial findings show improved anti-tumour activity using CAR T therapy in combination with atezolizumab. Since it is unclear how long after CAR T therapy atezolizumab treatment should begin, I will investigate and determine optimal atezolizumab dose timing.Aim 2 - Armouring CAR T Therapy against the PD1/PDL1 inhibitory pathway: I will develop an enhanced version of our CAR T therapy by reducing its sensitivity to PD1/PDL1-mediated inhibition in the absence of atezolizumab. To do so, I will overexpress a non-functional PD1 receptor on CAR T cells that outcompetes and thus blocks functional PD1 from receiving inhibitory signals.Significance This research will provide strong insights into strategies for enhancing CAR T therapy through blockade of PD1/PDL1 signalling.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529720
Name
Louie Taye
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Enhancing Chimeric Antigen Receptor (CAR) T Cell Therapy in Alveolar Soft Part Sarcoma through Extrinsic and Intrinsic Inhibition of the PD1/PDL1 Immune Checkpoint Axis
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Alveolar Soft Part Sarcoma; Chimeric Antigen Receptor (Car) T Cell Therapy; Immune Checkpoint Inhibition; Pd1/Pdl1 Checkpoint Axis; Tumour Microenvironment
Abstract
Background Alveolar soft part sarcoma (ASPS) is a highly metastatic cancer that is poorly managed by traditional treatment approaches. A new strategy known as chimeric antigen receptor (CAR) T cell therapy, where specialized killing cells of a patient immune system called T cells are engineered to selectively target their cancer, has proven effective. In a first-in-human trial, a CAR T therapy developed by our lab successfully eliminated many metastatic growths in a patient with ASPS; however, larger growths were non-responsive, likely due to activation of immune checkpoints by the cancer that suppress T cell activity. Further analysis of a non-responsive growth identified PDL1 as a highly expressed checkpoint protein, which sends inhibitory signals through interactions with its receptor, PD1, on T cells. Interestingly, atezolizumab, a PDL1 inhibitor, was recently approved for treating ASPS and may augment CAR T therapy. Enhancing CAR T Therapy with atezolizumab: In an ASPS mouse model, my initial findings show improved anti-tumour activity using CAR T therapy in combination with atezolizumab. Since it is unclear how long after CAR T therapy atezolizumab treatment should begin, I will investigate and determine optimal atezolizumab dose timing.Aim 2 - Armouring CAR T Therapy against the PD1/PDL1 inhibitory pathway: I will develop an enhanced version of our CAR T therapy by reducing its sensitivity to PD1/PDL1-mediated inhibition in the absence of atezolizumab. To do so, I will overexpress a non-functional PD1 receptor on CAR T cells that outcompetes and thus blocks functional PD1 from receiving inhibitory signals.Significance This research will provide strong insights into strategies for enhancing CAR T therapy through blockade of PD1/PDL1 signalling.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Louie, Taye
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~